Comparative analysis of the efficacy and safety of antibody‑drug conjugates, radionuclide‑drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment

作者：Huan Du, Xiao-Fei Hao, Binwei Lin, Yu Zhang, Luo Rui, Jing Wang, Mingming Tang, Decai Wang, Yihan Zhu, Jie Li, Tangzhi Dai, Yuchuan Yang, Xia Yang, Xiaobo Du · 发表于：Oncology Reports · 年份：2025 · DOI：10.3892/or.2025.9009 · 被引用次数：1 · 研究领域：Radiomics and Machine Learning in Medical Imaging、Gastric Cancer Management and Outcomes、HER2/EGFR in Cancer Research

Lu]Lu‑DOTA‑SYSA1801mAb exhibited strong tumor‑targeting ability, with significantly higher tumor uptake than other tissues. By day 145, the complete remission (CR) rate in the ADC group was 60%, with an overall survival (OS) rate of 60%. In the ADC→RDC group, the CR and OS rates were both 40%. The OS rates in the RDC, RDC→ADC, mAb and control groups were all 0%. The ADC group exhibited minimal changes in hematological parameters and hepatic/renal function, whereas the RDC and RDC→ADC groups showed more significant changes. These preclinical findings suggested that ADC monotherapy may demonstrate superior efficacy and safety profiles when compared with RDC monotherapy. Furthermore, sequential combination therapy that starts with ADC appears to be more favorable than approaches that start with RDC. Although ADC→RDC sequential therapy did not significantly outperform ADC monotherapy in this model, it may serve as an effective subsequent treatment strategy.